The Less Glamorous Biotech Opportunity Is the Cleanser Base

An October CBE JU report traces CARBOSURF research into Evonik's industrial rhamnolipid production and cosmetic applications. The facility opened in May 2024; this is a new account of commercialisation, not a new plant opening. The report also describes a separate EUR 80 million 2026 expansion for pharmaceutical-grade fermentation, which should not be relabelled as new cosmetics capacity.

Surfactants do unglamorous work in cleansing products. If a fermentation-derived input can meet performance, quality and cost requirements, it may move across many formulas without becoming a consumer-facing hero. The business question is substitution under real manufacturing constraints.

Supplier biodegradability language does not establish the environmental performance of a finished cleanser. Renewable feedstock does not resolve energy, purification, transport or packaging. Founders should ask for the exact grade, active content, test conditions, comparison basis, costed formula and dependable volume. Investors should distinguish pilot capability from qualified production and purchasing commitments.